- The development of all technical features and of high-quality, curated and adaptable CST content for the CST-Assistant v2.0 has been completed
- The new version of the CST-Assistant is a considerable upgrade of the product to meet key pain points and needs of CST therapists to support and scale the delivery of Cognitive Stimulation Therapy (CST) to people with dementia
- The CST-Assistant v2.0 will be released in
Denmark later in June and made available for partners in the COPI implementation project to gain relevant user information
- The completion of the CST-Assistant v2.0 is a key step in the preparation of
UK market entry of the product as a certified medical software in Q3 2023
Brain+ announces that it has completed the development of a significantly upgraded version 2.0 of the CST-Assistant and that the product will be released in the Danish market according to plan later in
This marks an important step also towards planned commercial release of the product as a medical device in the
The CST-Assistant will be introduced in the
Product function and impact: The CST-Assistant v2.0 is the culmination of 1 year of development work, based on comprehensive feedback gathered from CST therapist users and CST experts, including a Danish usability study conducted by
The therapists can use the product's adaptive functions to instantly tailor a full 7-week, 14 session CST program based on the particular characteristics a CST group participants, including age and physical capabilities - and in full accordance with the CST manual to ensure full clinical compliance. The result is not only that a therapist saves 50% of preparation time on average, but also that the therapy can be delivered in the highest quality in accordance with the CST principles which is crucial for the evidenced clinical effects of the therapy.
The technological platform, security requirements, data collection and user functionalities of the CST-Assistant v2.0 is the same across different country versions, but the CST activity content is culturally adapted to each country through a rigorously validated process with leading national CST experts. In the
Value proposition: The CST-Assistant v2.0 enables health systems, managing the care and treatment of people with dementia, to rapidly and cost-effectively scale their delivery of CST. In the
Next steps: Towards the
- establish a
UK entity to support the company'sUK activities - complete the ongoing usability study, conducted in partnership with AgeUK
-
have the CST-Assistant certified as a medical-device according to
UK regulatory requirements, including data protection.
Brain+ is on track to meet all three milestones.
Contact Information
CEO and Co-founder:
Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia by 2030.
https://news.cision.com/brain--a-s/r/the-cst-assistant-v2-0-is-now-ready-for-release-in-denmark-and-on-track-for-release-in-the-uk-end-of,c4001400
https://mb.cision.com/Main/20893/4001400/2865768.pdf
https://news.cision.com/brain--a-s/i/1-b-en-rgb,c3311220
(c) 2024 Cision. All rights reserved., source